Prostate Cancer Vaccine Provenge Faces Toughest Test Yet: The Real World

Last Updated Apr 29, 2010 2:47 PM EDT

The FDA's approval of Dendreon (DNDN)'s Provenge vaccine for prostate cancer (pictured) sweeps away past doubts about the company -- over the quality of its data and whether there was a conspiracy to manipulate its stock -- but brings the company four new tests: Until today, Dendreon and its flagship product have been the subject of rumor, speculation and outright fantasy. Those days are over. It's all hard data and real world experience from now on. Dendreon has delivered its pudding. The proof will be in the eating.

Image by Flickr user euthman, CC.